Keith Tapper
Stock Analyst at BMO Capital
(0.15)
# 4,116
Out of 4,820 analysts
6
Total ratings
16.67%
Success rate
-19.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $45 → $16 | $15.18 | +5.40% | 4 | Apr 14, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $1.77 | +182.49% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $14.71 | +110.74% | 1 | Jun 27, 2024 |
Neurogene
Apr 14, 2025
Maintains: Outperform
Price Target: $45 → $16
Current: $15.18
Upside: +5.40%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $1.77
Upside: +182.49%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $14.71
Upside: +110.74%